Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127787 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of DxN CMV Assay
A clinical trial, sponsored by Beckman Coulter.
- Terminated
- Registry status
- 19
- Enrollment target
NCT03127787 is a clinical trial that was terminated before completion, run by Beckman Coulter. The registered enrollment target is 19 participants.
The verdict
NCT03127787 was terminated before completion, sponsored by Beckman Coulter.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The DxN Cytomegalovirus (CMV) assay is an in vitro diagnostic assay intended as an aid in the management of CMV-infected individuals undergoing antiviral therapy. the purpose of the study is to establish the clinical performance of the DxN CMV Assay for plasma samples in the intended use population.
Interventions
- DIAGNOSTIC_TEST CMV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03127787
The ClinicalTrials.gov registry entry for NCT03127787 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beckman Coulter, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CMV Assay is the first listed.
NCT03127787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03127787 about?
NCT03127787 is a clinical study titled "Clinical Performance Evaluation of DxN CMV Assay". The DxN Cytomegalovirus (CMV) assay is an in vitro diagnostic assay intended as an aid in the management of CMV-infected individuals undergoing antiviral therapy. the purpose of the study is to establish the clinical performance of the DxN CMV Assay for plasma samples in the intended use population.
What is the current status of trial NCT03127787?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2016-06. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03127787?
The interventions under investigation include: CMV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03127787?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.